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Abstract 
Introduction:	Adrenocortical	carcinoma	(ACC)	is	a	rare	cancer	that	commonly	spreads	to	the	liver,	lungs	and	lymph	nodes.	Bone	metastases	are	infrequent.	
Objective	The	aim	of	this	report	was	to	describe	the	clinical	characteristics,	survival	perspective,	prognostic	factors	and	frequency	of	adverse	skeletal-related	events	(SREs)	in	patients	with	ACC	who	developed	bone	metastasis.	
Methods	This	is	a	retrospective,	observational,	multicenter,	multinational	study	of	patients	diagnosed	with	bone	metastases	from	ACC	who	were	treated	and	followed	up	in	three	European	countries	(France,	Italy	and	The	Netherlands)	and	one	center	in	the	United	States.	
Results	Data	of	156	patients	were	captured.	The	median	overall	survival	was	11	months.	SREs	occurred	in	47%	of	patients:	17%	bone	fractures,	17%	spinal	cord	compression,	1%	hypercalcemia,	12%	developed	more	than	one	SRE.	In	multivariate	analysis,	cortisol	hypersecretion	was	the	only	prognostic	factor	significantly	associated	with	a	higher	mortality	risk	(hazard	ratio	(HR)	2.24,	95%	confidence	interval	(CI):	1.19–4.23,	P = 0.013)	and	with	the	development	of	a	SREs	(of	border	line	significance).	The	administration	of	antiresorptive	therapies	(bisphosphonates	and	denosumab)	was	associated	with	a	lower	risk	of	death,	even	if	not	significant,	and	their	survival	benefit	appeared	confined	in	patients	attaining	serum	mitotane	levels	within	the	therapeutic	range.	
Conclusion	Bone	metastases	in	ACC	patients	are	associated	with	poor	prognosis	and	high	risk	of	SREs.	Cortisol	hypersecretion	was	the	only	prognostic	factor	suggesting	a	potential	benefit	from	antisecretory	medications.	The	therapeutic	role	of	bisphosphonates	and	denosumab	to	improve	patient	outcome	deserves	to	be	tested	in	a	prospective	clinical	trial.	
Introduction Adrenocortical	carcinoma	(ACC)	is	a	rare	and	aggressive	malignant	tumor,	with	an	incidence	of	0.5–2.0	new	cases	per	million	population	per	year	(1,	2).	The	mainstay	of	treatment	is	surgery	(1,	2,	3);	however,	many	patients	with	radically	resected	disease	are	destined	to	relapse	and	die	from	disease	(1,	2,	3,	4).	Patients	with	metastatic	disease	have	a	poor	prognosis	and	their	5-year	survival	is	less	than	15%	(1,	2).	Bone	metastases	are	not	frequently	reported	in	ACC.	In	a	large	European	Network	for	the	Study	of	Adrenal	Tumors	(ENSAT)	study,	involving	444	patients	with	stage	IV	ACC,	bone	metastases	(BM)	were	observed	in	32	patients	only	(7%)	(5).	Although	rare,	ACC	patients	with	metastatic	bone	disease	deserve	attention	since	bone	involvement	has	been	reported	to	greatly	impair	the	quality	of	life	in	cancer	patients	due	to	bone	pain	and	adverse	skeletal-related	events	(SREs),	such	as	pathological	fractures,	spinal	cord	and	nerve	root	compressions	and	hypercalcemia	(6).	In	addition,	the	occurrence	of	SREs	in	solid	tumors	is	frequently	associated	with	a	grim	prognosis	(7).	Actually,	there	are	no	data	available	on	the	natural	history	of	ACC	patients	with	BM,	the	frequency	and	distribution	of	SREs	and	the	prognostic	parameters.	Moreover,	several	prospective	randomized	clinical	trials	have	demonstrated	that	bone	resorption	inhibitors,	such	as	bisphosphonates	and	denosumab,	significantly	reduce	the	risk	of	SREs	in	bone	metastatic	patients	from	prostate,	breast,	lung	and	other	primary	malignancies	(8,	9,	10).	
 
 
 
No	data	are	available	on	the	efficacy	of	bone	resorption	inhibitors	in	the	management	of	ACC	patients	with	BM.	However,	on	the	basis	of	published	data	(11,	12,	13),	these	drugs	are	used	currently	in	ACC	patients	in	the	routine	clinical	practice.	This	multicenter,	multinational	study	was	undertaken	to	obtain	information	on	the	natural	history	of	BM	from	ACC	and	their	clinical	management.	The	primary	aim	was	to	define	the	overall	survival	of	this	population,	secondary	aims	were	(1)	frequency	and	type	of	SREs,	(2)	prognostic	factors,	(3)	efficacy	of	bone	resorption	inhibitors	in	the	SRE	prevention	and	disease	outcome.	
Patients and methods 
Study design This	was	a	retrospective,	observational,	multicenter	study	in	which	medical	records	of	patients	diagnosed	with	BM	from	ACC	who	were	treated	and	followed	up	in	referral	centers	in	three	European	countries	(France,	Italy	and	The	Netherlands)	and	one	US	center	were	analyzed.	Data	were	collected	from	adult	patients	of	all	ages	who	received	standard	treatments	in	accordance	with	their	treating	physician	practice	and	multidisciplinary	tumor	board	practice.	Only	patients	with	ACC	who	had	at	least	one	bone	metastasis	during	their	disease	course,	as	identified	by	bone	scan	or other imaging assessment (e.g. standard x-rays, computed 
tomography scans, PET-TC or magnetic resonance imaging of the skeleton), were included in the study. Patients with 
bone invasion by contiguity were excluded. 
Data collected at baseline and throughout the disease history included: Weiss score, Ki67, ENSAT stage at ACC 
diagnosis, time from diagnosis till the onset of BM, extraskeletal disease sites: local, visceral metastases, lymph-node 
involvement, hormonal status: presence/absence and type of hormone secretion, time to progression, time to the onset 
of first SRE and overall survival from the diagnosis of BM, type of SRE (bone fracture, hypercalcemia, spinal cord 
compression), radiation therapy in bone, skeletal surgery, treatment with bisphosphonates or denosumab. 
The ENSAT registry was approved by the local ethics committees (Comitato Etico Provinciale Provincia di Brescia c/o 
Spedali Civili, Comité de protection des personnes Ile de France IV, METC, Medical Ethical Review Committee, 
Máxima Medisch Centrum Veldhoven); the study was also approved by The University of Texas MD Anderson Cancer 
Center’s institutional review board. All patients included had given their written informed consent. 
 
Statistical analysis 
 
The primary end-point was overall survival in this patient population, which was defined as the time interval between 
the date of diagnosis of BM and the date of death or the last known alive date. The time between primary diagnosis and 
occurrence of BM and the time to the occurrence of SRE from the diagnosis of BM were also evaluated as secondary 
end points. Descriptive statistics were used for patient demographics, tumor characteristics and frequency of SREs. 
Categorized variables were expressed as percentages. 
The time to first SRE was defined as the interval between date of diagnosis of BM to the first occurrence of either 
clinical bone fracture, spinal cord compression or hypercalcemia. Patients without SREs were censored at the last 
follow-up or death. 
All survival curves were calculated by the Kaplan–Meier method and differences compared by the log-rank test. The 
Cox’s proportional hazards regression model was employed to assess the hazard ratios (HRs) and 95% confidence 
intervals (95% CIs) both in the univariate and multivariate analysis, with the lowest risk group as the reference group. 
The parameters associated with OS or time to SRE in the univariate analysis (at P ≤ 0.10) were included in the 
multivariate analysis model. 
Heterogeneity in the effect of bisphosphonate/denosumab therapy in subgroups of patients was evaluated with the use 
of standard tests for interaction. Missing data were dealt with by excluding patients from particular analyses if their files 
did not contain data for the required variables. All reported P values are two-sided and P values less than 0.05 were 
considered to indicate statistical significance. 
SPSS statistical software (version 17.00) was used for statistical analysis. A P value of 0.05 was considered statistically 
significant. Due to the absence of any published data on the clinical outcome of bone metastatic ACC and the 
explorative nature of this study, a formal calculation of the sample size was not performed. It was considered, however, 
that a minimum of 100 patients would have been required to have an adequate power for statistical analyses. 
 
Results		
Patient	characteristics	and	treatment	administered	
	Data	of	a	total	number	of	156	ACC	patients	with	BM	were	captured:	59	from	Gustave	Roussy	and	Cochin	hospitals	in	Paris	(France),	17	from	Medical	Oncology	Unit	in	Brescia	and	Internal	Medicine	in	Orbassano	(Italy),	21	from	several	centers	in	Netherlands	and	59	from	University	of	Texas	MD	Anderson	Cancer	Center	in	the	United	States.	These	patients	were	identified	from	1995	to	2016	after	reviewing	the	records	of	1129	ACC	patients	with	metastatic	disease	followed	in	the	participating	institutions.	The	proportion	of	bone	involvement	in	metastatic	ACC	in	this	series	was	13.8%	(156/1129).	Patient	demography	and	tumor	characteristics	are	described	in	Table	1.			
	
Table	1	Patient and tumor characteristics.                       
 
Characteristics   Values 
n 156 
Age: median (range) 53 (17–87) 
Gender 
 Male 51 (33%) 
 Female 105 (67%) 
Extraskeletal disease sites 
 Lung 91 (59%) 
 Liver 83 (54%) 
 Lymphnodes 41 (27%) 
 Other 40 (25%) 
Number of metastatic sites 
 Bone only 14 (9%) 
 2 metastatic sites 61 (39%) 
 More than two sites 76 (49%) 
Hormone secretion profile 97 (62%) 
 No secretion 57 (37%) 
 Missing  2 (1%) 
 Only cortisol 46 (29%) 
 Cortisol + androgens 18 (12%) 
 Cortisol (± androgens) + other hormones 17 (11%) 
 Androgens only 12 (8%) 
 Estrogens only 1 (1%) 
 Mineral-corticoids only 0 
Bone metastases 
 Synchronous 60 (38%) 
 Metachronous 95 (61%) 
 Missing 1 (1%) 
Time to onset bone metastases from ACC diagnosis (months) 
 Median (range) 6 (0–122) 
Previous treatments for local regional disease 
 Adrenal surgery 115 (74%) 
 No adrenal surgery  35 (22%) 
 Missing 6 (4%) 
 Adjuvant mitotane 41 (26%) 
Treatments for metastatic disease before bone metastases diagnosis 
 Chemotherapy ± mitotane 47 (30%) 
 Mitotane 14 (9%) 
Antineoplastic treatment after bone metastasis diagnosis 
 Chemotherapy 62/119 (40%) 
 Mitotane (alone) 16/119 (10%) 
 No treatment 41 (26%) 
 Missing 37 (24%) 
Other treatments 
 Bone surgery 36/139 (23%) 
 Missing 17 (11%) 
Bone radiation therapy 75 /139 (48%) 
 Missing 17 (11%) 
Bisphosphonates 31/135 (23%) 
 Missing 21 (13%) 
Denosumab (± bisphosphonates) 10 /135 (7%) 
 Missing 21 (13%) 
___________________________________________________ ______________________ 
 	
					The	median	age	was	53	years,	male/female	ratio	was	1/2	(51/105).	Sixty/156	(38%)	had	bone	metastasis	at	the	time	of	ACC	diagnosis	and	95/155	(61%)	developed	bone	metastasis	during	follow-up.	Ninety-seven	out	of	154	assessable	patients	(62%)	had	hormone	hypersecretion,	which	consisted	in	either	cortisol	alone	in	46	patients	(29%)	or	in	association	with	androgens	and/or	other	hormones	in	35	patients	(23%),	androgens	alone	in	12	patients	(8%)	and	estrogen	alone	in	1	patient	(0.6%).	One	patient	had	both	androgen	and	mineral	corticoid	hypersecretion,	while	in	the	remaining	two	patients,	the	hormones	produced	in	excess	were	not	specified.	Bone	was	the	only	metastatic	site	in	14	patients	(9%),	in	91%	of	patients	BM	were	associated	with	other	metastatic	sites,	visceral	(liver	and	lung)	in	particular.	Previous	treatments	before	the	diagnosis	of	BM	consisted	in	adrenal	surgery	in	115	patients	(74%)	associated	with	adjuvant	mitotane	in	41	patients	(26%).	Forty-seven	patients	(30%)	had	received	chemotherapy	with	or	without	mitotane	or	mitotane	alone	for	advanced	disease.	After	the	diagnosis	of	BM,	62	patients	(40%)	received	chemotherapy	with	or	without	mitotane	and	16	patients	(10%)	mitotane	alone.	Forty-one	patients	(26%)	did	not	receive	any	systemic	antineoplastic	therapy.	In	the	remaining	37	patients	(24%)	there	were	no	information	on	treatment	received.	Mitotane	within	the	therapeutic	range	(14–20 mg/L)	was	observed	in	62	out	of	107	available	patients	(58%).	Thirty-seven	out	of	135	evaluable	patients	(27%)	received	bone	resorption	inhibitors:	31	(23%)	bisphosphonates	and	6	(4%)	denosumab.	Four	patients	(3%)	received	both	bisphosphonates	and	denosumab.			
Patient	prognosis	
	Median	follow-up	of	patients	was	12	months	(range,	1–217).	At	the	last	follow-up	examination,	132	patients	(85%)	were	dead.	Median	overall	survival	from	the	diagnosis	of	bone	metastasis	was	11	months	(95%	CI:	7–14)	(Fig.	1).	Among	the	22	potential	prognostic	factors	analyzed	in	univariate	analysis,	cortisol	hypersecretion	and	liver	metastases	were	the	variables	significantly	associated	with	an	increased	risk	of	death.	Conversely,	surgery	for	primary	disease,	bone	surgery,	radiation	therapy	for	BM,	the	use	of	bone	resorption	inhibitors	(bisphosphonates	and/or	denosumab)	and	serum	mitotane	levels	>14 mg/L,	measured	after	diagnosis	of	metastatic	disease,	were	significantly	associated	with	a	decreased	risk	of	death.	The	remaining	variables:	sex,	lung,	lymph	nodes	or	other	metastases,	skeletal	complications,	such	as	pathological	fractures,	hypercalcemia	and	spinal	cord	compression,	number	of	metastatic	sites	failed	to	show	any	association	with	survival.	Moreover,	we	did	not	observe	any	difference	in	overall	survival	comparing	metacronous	(median	OS	10.93	months	(95%	CI,	6.24–15.62))	versus	synchronous	BM	(median	OS	10.86	months	(95%	CI,	5.33–16.40),	P,	0.578)	and	chemotherapy	administration	after	the	diagnosis	of	BM	was	not	associated	to	a	survival	improvement		(Table	2).	Ki67	and	Weiss	score	were	available	in	only	39	and	28	patients	respectively.	So	these	two	parameters	were	not	included	in	the	statistical	analyses.	In	multivariate	analysis,	only	cortisol	hypersecretion	(hazard	ratio	(HR)	2.240,	95%	CI:	1.188–4.226,	P = 0.013)	maintained	a	significant	association	with	the	death	risk.	Mitotane	levels	and	bisphosphonate/denosumab	therapy	just	failed	to	be	significantly	associated	with	overall	survival	(Table	2).	
We further explored the prognostic role of the administration of bisphosphonates/denosumab stratifying patients 
according to cortisol hypersecretion, bone radiation therapy and mitotane serum levels in a multivariate analysis. The 
effect of bisphosphonate/denosumab therapy on overall survival did not differ according to the secretion status or 
whether the patients received bone radiation therapy or not (Fig. 1) and Supplementary materials, see section on 
supplementary data given at the end of this article). 
Conversely bisphosphonate/denosumab therapy was associated with a significantly lower risk of death in patients 
attaining serum mitotane levels >14 mg/L (HR 0.42, 95% CI: 0.22–0.80, P 0.006) but not in those who did not (HR 
1.00, 95% CI: 0.47–2.13, P 0.997) (Fig. 2). The difference between the two HRs was statistically significant at the 
interaction test (P = 0.036) after adjusting for cortisol hypersecretion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 
(A) Overall survival of the entire patient population; (B) probability of undergoing adverse skeletal-related events 
(fractures, spinal cord compression, hypercalcemia). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 	
Table	2.	Prognostic	factors	for	overall	survival	according	to	univariate	and	multivariate	Cox	analysis.	________________________________________________________________________________________________________________________________________________	
Overall	survival	 Death/n	 Missing		 Total	
Univariate	analysis	 Multivariate	HR	(95%	CI)	 P	 HR	(95%	CI)	 P	Gender		 Female	 95/105	 0	 105	 0.82	(0.56–1.21)	 0.33	 	 		 Male	 36/51	 0	 51	 1	 	 	 	Age	ACC	dg		 >50	 51/64	 0	 64	 1.40	(0.97–2.03)	 0.07	 1.07	(0.61–1.89)	 0.810		 <50	 81/92	 0	 92	 1	 	 1	 	Cortisol	hypersecretion		 Yes	 75/81	 0	 81	 1.91	(1.31–2.79)	 0.001	 2.24	(1.19–4.23)	 0.013		 No	 46/61	 0	 61	 1	 	 1	 Mitotane	level		 ≥14	 53/62	 0	 62	 0.41	(0.27–0.64)	 0.000	 0.61	(0.34–1.08)	 0.089		 <14	 37/45	 0	 45	 1	 	 1	 	Adrenal	surgery		 Yes	 98/115	 0	 115	 0.56	(0.36–0.86)	 0.009	 1.17	(0.60–2.29)	 0.65		 No	 29/35	 0	 35	 1	 	 1	 	Syncronous	mets		 Yes	 50/60	 0	 60	 1.106	(0.774–1.581)	 0.58	 	 		 No	 81/95	 0	 95	 1	 	 	 	Liver	mets		 Yes	 72/83	 0	 83	 1.637	(1.142–2.345)	 0.007	 1.563	(0.876–2.788)	 0.130		 No	 58/70	 0	 70	 1	 	 	 	Lung	mets		 Yes	 78/91	 0	 91	 0.987	(0.694–1.403)	 0.94	 	 		 No	 53/63	 0	 63	 1	 	 	 	Lymphnodes		 Yes	 30/41	 0	 41	 1.211	(0.797–1.840)	 0.37	 	 		 No	 96/108	 0	 108	 1	 	 	 	Other	mets		 Yes	 35/41	 0	 41	 0.880	(0.590–1.314)	 0.53	 	 		 No	 97/115	 0	 115	 1	 	 	 	0–1	metastatic	site	 67/79	 0	 79	 1	 	 	 	2	metastatic	sites	 39/45	 0	 45	 0.984	(0.593–1.515)	 0.82	 	 	≥3	metastatic	sites	 26/32	 0	 32	 1.290	(0.769–2.164)	 0.33	 	 	Pathological	fracture		 Yes	 36/42	 0	 42	 0.822	(0.553–1.222)	 0.33	 	 		 No	 82/100	 0	 100	 1	 	 	 	Spinal	compression		 Yes	 33/43	 0	 43	 0.946	(0.632–1.416)	 0.79	 	 		 No	 85/99	 0	 99	 1	 	 	 	Hypercalcemia		 Yes	 1/2	 0	 2	 3.715	(0.508–27.192)	 0.19	 	 		 No	 117/140	 0	 140	 1	 	 	 	Bone	surgery		 Yes	 30/36	 0	 36	 0.435	(0.281–0.675)	 0.000	 0.663	(0.329–1.217)	 0.170		 No	 85/103	 0	 103	 1	 	 	 	Bone	radiation	therapy		 Yes	 61/75	 0	 75	 0.479(0.328–0.700)	 0.000	 0.655	(0.346–1.240)	 0.194		 No	 55/64	 0	 64	 1	 	 	 	Denosumab/bisphosphonate		 Yes	 30/37	 0	 37	 0.562	(0.367–0.861)	 0.008	 0.540	(0.286–1.020)	 0.058		 No	 84/98	 0	 98	 1	 	 	 	Chemotherapy ± mitotane*		 Yes	 53/62	 0	 62	 1.292	(0.732–2.279)	 0.377	 	 		 No	 32/41	 0	 41	 1	 	 	 			*First	oncological	treatment	chemio + mito/nothing.			
					
		
Figure 2 
Effects of bisphosphonate/denosumab use on overall survival in (A) patients with mitotane ≤14 mg/L; (B) patients with 
mitotane >14 mg/L. 
 
 
 
 
 
 
  
Skeletal-related events 
Seventy out of 148 evaluable patients (47%) developed at least one SRE: 26/148 (17%) only bone fractures, 1/148 (1%) 
only hypercalcemia and 26/148 (17%) only spinal cord compression. Sixteen patients out of 148 (11%) presented both 
pathological fractures and spinal cord compression, one (1%) patient developed both hypercalcemia and spinal cord 
compression (Fig. 3A). In 46 patients (29%), a SRE was detected within 1 month from the diagnosis of BM.  
 
 
 
Figure 3  
 Proportion of patients undergoing skeletal-related events; (B) proportion of patients undergoing skeletal-related events according to the presence or 
absence of glucocorticoid hypersecretion. 
 
It is likely that SREs led to diagnosis of BM in most of these cases. Thirty-six out of 139 evaluable patients (26%) underwent 
bone surgery and 75/139 (54%) radiation therapy in bone. 
The distribution of skeletal events according to cortisol status was 37/75 (49%) in patients with cortisol hyper secretion 
(12/75 (16%) skeletal fractures, 15/75 (20%) spinal cord compression, 9/75 (12%) both spinal cord compression and 
pathological fractures and 1/75 (1%) both hypercalcemia and spinal cord compression) and 25/59 (42%) in those without 
hyper secretion (11/59 skeletal fractures (19%), 7/59 spinal cord compression (12%), 6/59 (10%) both spinal cord 
compression and pathological fracture, 1/59 (1%) hypercalcemia) (Fig. 3B).  Only 12 patients out of 156 had pure androgen 
secretion. Among them 4 out of 12 (30%) developed an SRE. 
 
 
 The greater proportion of spinal cord compression in patients with cortisol hypersecretion did not attain the statistical 
significance (P = 0.20). Cortisol hypersecretion was significantly associated with a greater risk to develop a SRE in 
univariate analysis; however, it did not maintain a significant independent role in multivariate analysis (Table 3). We also 
analyzed the predictive role of several parameters for the occurrence over time of either bone fractures or spinal cord 
compression assessed separately. As depicted in Supplementary Tables 1 and 2, none of the parameters evaluated were 
associated with bone fractures (Supplementary Table 1), while cortisol hypersecretion was predictive of an increased risk of 
spinal cord compression (Supplementary Table 2) (HR 2.21, 95% CI: 1.10–4.44, P = 0.026).  
Table 3 Predictive factors for the time to the occurrence of adverse skeletal events according to univariate and multivariate Cox analysis. 
Skeletal-related events 
Missing Total 
Univariate analysis                        Multivariate 
 Events/n HR (95% CI) P                                 HR (95% CI)        P 
Gender 
 Female 48/99  6 105 1 (0.608–1.690) 0.958   
 Male 23/49 2 51 1.014    
Age ACC dg 
 >50 29/86   1.267 (0.775–2.069) 0.345   
 <50 27/62   1    
Cortisol hypersecretion 
 Yes 38/75 6 81 1.748 (1.019–2.998) 0.043 5.848 (0.703–48.655)                   0.102 
 No 24/59 2 61 1  1  
Mitotane level 
 ≥14 33/62  0 62 0.914 (0.489–1.709) 0.778   
 <14 17/45 0 45 1    
Adrenal surgery 
 Yes 51/109 6 115 0.662 (0.372–1.175) 0.159   
 No 17/33 2 35 1    
Synchronous mets 
 Yes 28/57 3 60 1.179 (0.723–1.921) 0.509   
 No 43/91 4 95 1    
Liver mets 
 Yes 38/82 1 83 1.148 (0.705–1.870) 0.578   
 No 31/64 6 70     
Lung mets 
 Yes 42/89 2 91 0.974 (0.597–1.590) 0.917   
 No 28/58 5 63 1    
Lymphnodes 
 Yes 19/39 2 41 1.353 (0.782–2.340) 0.280   
 No 48/104 4 108 1    
Other mets 
 Yes 18/37 4 41 0.869 (0.495–1.526) 0.624   
 No 53/111 4 115 1    
0–1 metastatic site 35/73 6 79 1    
2 metastatic sites 22/44 1 45 1.098 (0.587–2.054) 0.770   
3 or 4 metastatic sites 14/31 1 32 1.236 (0.623–2.453) 0.544   
Bone surgery 
 Yes 26/35 1 36 1.455 (0.861–2.459) 0.161   
 No 39/97 6 103 1    
Bone radiation therapy 
 Yes 41/69 6 75 1.062 (0.628–1.796) 0.823   
 No 25/62 2 64 1    
Denosumab/bisphosphonates 
 Yes 26/37 0 37 1.627 (0.967–2.737) 0.067 1.494 (0.261–8.545) 0.652 
 No 36/97 1 98 1  1  
Antineoplastic treatments after BM diagnosis 
 0 18/37 4 41 1    
 Mitotane 6/13 3 16 1.382 (0.745–2.564) 0.304   
 Chemotherapy 23/61 1 62 1.405 (0.530–3.725) 0.494   
 Discussion 
This retrospective, multicentric study of the ENSAT network with the cooperation of the MD Anderson Cancer Center 
retrieved data of a consistent number of ACC patients with BM allowing definition of the survival perspective, the frequency 
of adverse SREs and to identify prognostic factors affecting the patient outcome. 
The results showed that bone involvement from ACC was observed in about 14% of advanced ACC patients and that bone 
metastastatization portends a limited survival perspective (median, 11 months). However, the life expectancy of such patients 
is alike to advanced ACC patients enrolled in the FIRM-ACT trial (14). Bone was the single metastatic site in only 9% of 
patients, while in most patients BM were diagnosed concomitantly to other metastatic sites (visceral metastases in particular). 
Usually, BM were not synchronous to the primary tumor and metachronous metastases occurred late in the course of disease 
(15). The number of sites involved, a strong independent prognostic factor in advanced ACC (5), failed to be prognostic in 
this series. Probably because most cases had multiple sites involved. 
Cortisol hypersecretion was the strongest prognostic factor, confirming the negative effect of this condition on patient 
outcome, as previously reported (16, 17). In mitotane-treated patients, blood drug levels above 14 mg/L were associated with 
better outcome that just failed to be statistically significant in multivariate analysis (18, 19). As to the treatment administered, 
only 52% of patients received a specific antineoplastic therapy, 40% of patients have been already submitted to 
chemotherapy and mitotane, or both, before the diagnosis of BM, and these patients could have been judged ineligible for 
further therapies when BM became apparent. However, chemotherapy administered after the diagnosis of BM failed to 
improve the patient prognosis. 
Due to the retrospective nature of this study, we did not have information on patient performance status and co-morbidities, 
and this is a limitation. 
The clinical outcome of ACC patients with BM was frequently complicated by the occurrence of SREs, since 47% of patients 
had at least 1 SRE, mainly fractures and spinal cord compression. The proportion of patients with a SRE in this series is 
higher than that observed in other multicenter retrospective series involving bone metastatic patients from colon (17.8%) 
(20), lung (26.4%) (21) and kidney cancer (24%) (22). A recent retrospective study showed that thyroid cancer patients with 
BM had a similar proportion of SREs (43.4%) to that of the present series (23). It should be noted, however, that bone 
metastatic patients with thyroid cancer have a quite long survival perspective that predisposes them to develop SREs. In this 
series, SREs prompted the diagnosis of BM in one-third of cases, suggesting that in many ACC patients the occurrence of an 
SRE led to diagnosis of BM. SREs were more frequently observed in patients with cortisol hypersecretion, a finding that 
could be explained by a contributing effect of elevated cortisol levels on bone fragility (24). When the type of SREs were 
analyzed separately, however, cortisol hypersecretion was associated with a greater risk of spinal cord compression, that is 
usually due to tumor invasion in the spinal canal, but not with skeletal fractures. These data suggest a major contribution of 
cortisol secretion in favoring the disease progression in bone. Conversely, hypercalcemia was rare. Hypercalcemia in solid 
tumors is associated with the ectopic production of parathyroid related peptides (PTHrP) (25). PTHrp was frequently 
detected in ACC tumors by immunohistochemistry and PTHrp immunostaing was associated with poor prognostic features 
(26). The potential inhibitory effect of elevated cortisol levels on circulating PTHrP levels (27) could provide a possible 
explanation on why hypercalcemia in our series was rare despite the frequent PTHrP secretion by ACC (28). 
In prospective randomized clinical trials testing the efficacy of bisphosphonates and denosumab in the management of bone 
metastatic patients (29, 30), bone surgery and bone radiation therapy were included in the definition of SRE. In the present 
series, we adopted a stricter definition because bone surgery and radiation therapy are treatments and not negative events. As 
a matter of fact, both treatment modalities were associated with an improved survival in univariate analysis. 
Bone resorption inhibitors have demonstrated to decrease the frequency of SREs in patients with BM from breast, prostate 
and lung cancer (11, 12, 13). In the present series, these drugs were administrated in one third of patients and their use failed 
to be associated with a reduced incidence of SREs. We do not have information about the date of start of bone resorption 
inhibitors, the inverse association between the onset of SRE and the use of bisfosfonates/denosumab suggest that in most 
cases these drugs were administered after the onset of the first SRE. 
Noteworthy, the administration of bone resorption inhibitors in this study was associated with a longer survival but it failed 
to attain the statistical significance in multivariate analysis. It is known that these drugs may act as specific cytotoxic agents, 
as demonstrated by several preclinical studies (31, 32) including one on ACC (33) or may influence the prognosis indirectly 
by inhibiting the activity of the bone metastatic niche and preventing cancer colonization outside the bone microenvironment 
(31). Interestingly, in the present series, the efficacy of these drugs in improving survival seemed confined in the patient 
subset attaining mitotane serum levels within the therapeutic range. These data suggest a possible synergism between the two 
drugs to be confirmed in in vitro and in vivo studies. 
The retrospective nature of this study is the main limitation and the statistical analyses performed should be considered 
explorative and hypothesis generating. 
Prospective studies are needed to establish the real benefit of antiresorptive therapies to reduce SRE as well as in improving 
overall survival of ACC patients. 
In conclusion, this multicenter, multinational, retrospective study demonstrates that the appearance of BM complicates 
dramatically the natural history of ACC, since they are associated with poor prognosis and high risk of SREs. Cortisol 
hypersecretion was the main negative prognostic parameter and bisphosphonate (or denosumab) administration may be 
associated with a survival improvement, particularly in patients with mitotane levels within the therapeutic range. 
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